This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
PCSK9
From Proteopedia
| (16 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | <StructureSection load=' | + | <StructureSection load='' size='400' side='right' caption='Structure of human PCSK9 catalytic domain (blue) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry [[2w2m]])' scene='55/553967/Cv/2' pspeed='8'> |
| - | + | == Function == | |
| - | '''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase | + | '''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is part of the cholesterol synthesis<ref>PMID:17502100</ref>. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. See details in [[Pro-protein convertase subtilisin/kexin type 9 (PCSK9)]]. |
| + | == Relevance == | ||
| + | Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood<ref>PMID:23317404</ref>. Inhibition of PCSK9 results in increased pathogen lipid clearance, decreased inflammatory response and improved septic shock outcome<ref>PMID:25320235</ref>. | ||
| + | |||
| + | == Structural highlights == | ||
| + | *<scene name='55/553967/Cv/7'>PCSK9 catalytic domain interactions with LDL receptor EGF-A domain</scene>. Water molecules are shown as red spheres. | ||
| + | *<scene name='55/553967/Cv/8'>PCSK9 Ca coordination site</scene>. | ||
| + | *<scene name='55/553967/Cv/9'>LDL receptor Ca coordination site</scene>. | ||
| + | </StructureSection> | ||
==3D structures of PCSK9== | ==3D structures of PCSK9== | ||
| Line 10: | Line 18: | ||
[[3bps]], [[2w2m]], [[3gcx]] – hPCSK9 + LDLR EGF-A <br /> | [[3bps]], [[2w2m]], [[3gcx]] – hPCSK9 + LDLR EGF-A <br /> | ||
[[2w2n]], [[3gcw]] – hPCSK9 + LDLR EGF-A (mutant)<br /> | [[2w2n]], [[3gcw]] – hPCSK9 + LDLR EGF-A (mutant)<br /> | ||
| - | [[2w2o]], [[2w2p]], [[2w2q]] – hPCSK9 (mutant) + LDLR EGF-A | + | [[2w2o]], [[2w2p]], [[2w2q]], [[7kev]], [[7kfa]] – hPCSK9 (mutant) + LDLR EGF-A <br /> |
| - | + | ||
[[2xtj]], [[3sqo]], [[4k8r]] – hPCSK9 + antibody <br /> | [[2xtj]], [[3sqo]], [[4k8r]] – hPCSK9 + antibody <br /> | ||
| + | [[3h42]] – hPCSK9 (mutant) + antibody <br /> | ||
| + | [[6e4y]], [[6e4z]], [[6mv5]] – hPCSK9 N terminal + antibody <br /> | ||
| + | [[6u26]], [[6u2n]], [[6u2p]] – hPCSK9 + inhibitor<br /> | ||
| + | [[6u2f]], [[6u36]], [[6u38]], [[6u3i]], [[6u3x]] – hPCSK9 + antibody + inhibitor<br /> | ||
| + | [[6xib]], [[6xic]], [[6xid]], [[6xie]], [[6xif]], [[7s5h]] – hPCSK9 + peptide <br /> | ||
| + | [[7s5g]] – hPCSK9 + peptide + inhibitor<br /> | ||
| + | [[6u2f]], [[6u3i]] – hPCSK9 + antibody + peptide inhibitor<br /> | ||
[[3m0c]] – hPCSK9 (mutant) + LDLR <br /> | [[3m0c]] – hPCSK9 (mutant) + LDLR <br /> | ||
[[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br /> | [[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br /> | ||
| + | [[4ov6]] – hPCSK9 + adnectin <br /> | ||
| + | [[7anq]] – hPCSK9 C terminal + VHH minibody <br /> | ||
| + | [[6olz]], [[6om0]], [[6om7]] – hPCSK9 in ribosome – Cryo EM <br /> | ||
| + | |||
| + | == References == | ||
| + | <references/> | ||
| + | |||
| + | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
3D structures of PCSK9
Updated on 05-December-2021
2p4e, 2pmw, 2qtw – hPCSK9 – human
3bps, 2w2m, 3gcx – hPCSK9 + LDLR EGF-A
2w2n, 3gcw – hPCSK9 + LDLR EGF-A (mutant)
2w2o, 2w2p, 2w2q, 7kev, 7kfa – hPCSK9 (mutant) + LDLR EGF-A
2xtj, 3sqo, 4k8r – hPCSK9 + antibody
3h42 – hPCSK9 (mutant) + antibody
6e4y, 6e4z, 6mv5 – hPCSK9 N terminal + antibody
6u26, 6u2n, 6u2p – hPCSK9 + inhibitor
6u2f, 6u36, 6u38, 6u3i, 6u3x – hPCSK9 + antibody + inhibitor
6xib, 6xic, 6xid, 6xie, 6xif, 7s5h – hPCSK9 + peptide
7s5g – hPCSK9 + peptide + inhibitor
6u2f, 6u3i – hPCSK9 + antibody + peptide inhibitor
3m0c – hPCSK9 (mutant) + LDLR
3p5b, 3p5c – hPCSK9 + LDLR variant
4ov6 – hPCSK9 + adnectin
7anq – hPCSK9 C terminal + VHH minibody
6olz, 6om0, 6om7 – hPCSK9 in ribosome – Cryo EM
References
- ↑ Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007 May;15(5):545-52. PMID:17502100 doi:http://dx.doi.org/10.1016/j.str.2007.04.004
- ↑ Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des. 2013;19(17):3161-72. PMID:23317404
- ↑ Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014 Oct 15;6(258):258ra143. doi: 10.1126/scitranslmed.3008782. PMID:25320235 doi:http://dx.doi.org/10.1126/scitranslmed.3008782
